NASDAQ:CORI - Corium International Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$12.68
+0.30 (1.20%)
Get New Corium International Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CORI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CORI

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Corium International in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $12.68.

This chart shows the closing price for CORI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Corium International. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/31/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/27/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/24/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/15/2018Needham & Company LLCDowngradeBuy ➝ HoldLow
10/15/2018HC WainwrightDowngradeBuy ➝ Neutral$13.00Low
8/13/2018HC WainwrightReiterated RatingBuy$13.00High
8/10/2018Cantor FitzgeraldReiterated RatingBuy$14.00High
5/18/2018Cantor FitzgeraldReiterated RatingBuy$14.00Low
5/15/2018HC WainwrightSet Price TargetBuy$14.00High
3/27/2018Cantor FitzgeraldReiterated RatingBuy$14.00High
2/9/2018HC WainwrightSet Price TargetBuy$14.00Low
12/27/2017HC WainwrightSet Price TargetBuy ➝ Buy$15.00 ➝ $14.00Low
12/26/2017Needham & Company LLCLower Price TargetBuy ➝ Buy$16.00 ➝ $14.00High
12/22/2017Cantor FitzgeraldReiterated RatingBuy$14.00Low
11/20/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$13.00 ➝ $16.00N/A
11/17/2017HC WainwrightSet Price TargetBuy$15.00N/A
10/29/2017Jefferies Financial GroupSet Price TargetBuy$10.00N/A
9/27/2017Cantor FitzgeraldReiterated RatingBuy$12.00High
9/26/2017HC WainwrightInitiated CoverageBuy ➝ Buy$15.00Medium
9/17/2017Needham & Company LLCReiterated RatingBuy$13.00Medium
8/7/2017Jefferies Financial GroupReiterated RatingBuy ➝ Buy$8.00 ➝ $10.00Low
7/19/2017Jefferies Financial GroupReiterated RatingBuy$8.00Low
7/7/2017WBB SecuritiesUpgradeBuy$13.00Low
5/12/2017Cantor FitzgeraldReiterated RatingOverweight$10.00 ➝ $12.00High
4/20/2017Jefferies Financial GroupSet Price TargetBuy$8.00Low
4/18/2017FBR & Co.Reiterated RatingOutperform ➝ Outperform$12.00 ➝ $13.00Low
4/14/2017Needham & Company LLCReiterated RatingBuy$10.00N/A
3/21/2017FBR & Co.Reiterated RatingBuyLow
3/17/2017Jefferies Financial GroupReiterated RatingBuy$8.00Low
2/15/2017Jefferies Financial GroupLower Price TargetBuy$9.00 ➝ $8.00N/A
2/14/2017Cantor FitzgeraldSet Price TargetBuy$10.00N/A
2/14/2017FBR & Co.Set Price TargetBuy$12.00N/A
2/14/2017Needham & Company LLCLower Price TargetBuy$12.00 ➝ $10.00N/A
1/18/2017FBR & Co.Set Price TargetBuy$18.00N/A
1/6/2017Cantor FitzgeraldReiterated RatingBuy$10.00N/A
1/4/2017SVB LeerinkReiterated RatingBuyN/A
12/16/2016Cantor FitzgeraldInitiated CoverageOverweight$10.00N/A
11/24/2016Jefferies Financial GroupSet Price TargetBuy$9.00N/A
11/22/2016SVB LeerinkSet Price TargetBuy$16.00N/A
11/22/2016FBR & Co.Reiterated RatingBuy$18.00N/A
(Data available from 10/24/2016 forward)

News Sentiment Rating

-0.10 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/26/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
7/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/25/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/24/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/24/2021

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Corium International logo
Corium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening. The company's products under pipeline comprise Twirla, a combination hormonal contraceptive patch, which has completed Phase III clinical trials to deliver ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system that has completed Phase 1 and Phase II a clinical trials for the treatment of severe osteoporosis; and Donepezil and Memantine transdermal systems, which completed Phase I clinical trials for the treatment of Alzheimer's disease. In addition, it develops Aripiprazole TDS for the treatment for psychiatric disorders; Corplex Ropinirole, a transdermal patch for the treatment of Parkinson's disease; and Motion Sickness Patch, a generic transdermal product for the prevention of nausea and vomiting associated with motion sickness. Corium International, Inc. has collaboration agreements with The Procter & Gamble Company; Teva Pharmaceuticals USA, Inc.; Agile Therapeutics, Inc.; and Aequus Pharmaceuticals, Inc. The company was incorporated in 1995 and is headquartered in Menlo Park, California.
Read More

Today's Range

Now: $12.68
Low: $12.68
High: $12.68

50 Day Range

MA: N/A

52 Week Range

Now: $12.68
Low: $7.17
High: $13.93

Volume

N/A

Average Volume

577,723 shs

Market Capitalization

$459.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.87

Frequently Asked Questions

What sell-side analysts currently cover shares of Corium International?

The following Wall Street research analysts have issued research reports on Corium International in the last twelve months:
View the latest analyst ratings for CORI.

What is the current price target for Corium International?

0 Wall Street analysts have set twelve-month price targets for Corium International in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Corium International in the next year.
View the latest price targets for CORI.

What is the current consensus analyst rating for Corium International?

Corium International currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CORI.

How do I contact Corium International's investor relations team?

Corium International's physical mailing address is 235 CONSTITUTION DRIVE, MENLO PARK CA, 94025. The biopharmaceutical company's listed phone number is 650-298-8255 and its investor relations email address is [email protected] The official website for Corium International is www.coriumgroup.com.